2019
The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma
Ziccheddu B, Biancon G, De Philippis C, Bagnoli F, Maura F, Dugo M, Devecchi A, De Cecco L, Sensi M, Terragna C, Martello M, Bagratuni T, Kastritis E, Dimopoulos M, Cavo M, Carniti C, Montefusco V, Corradini P, Bolli N. The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma. Blood 2019, 134: 3056. DOI: 10.1182/blood-2019-122197.Peer-Reviewed Original ResearchMultiple myelomaSpeakers bureauProteasome inhibitorsTP53 mutationsAdvisory CommitteeHigh-dose melphalanMedian overall survivalHigh-risk featuresRefractory multiple myelomaTime of transplantHigh-risk lesionsLine of treatmentNext-generation sequencingBulk tumor populationWhole-exome sequencingInfluence of treatmentMCL1 upregulationOverall survivalRefractory casesComplete responseDisease courseMM patientsPrognostic valueImmunomodulatory agentsPathogenetic role
2018
Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA A Pilot Study
Biancon G, Gimondi S, Vendramin A, Carniti C, Corradini P. Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA A Pilot Study. Journal Of Molecular Diagnostics 2018, 20: 859-870. PMID: 30165206, DOI: 10.1016/j.jmoldx.2018.07.006.Peer-Reviewed Original ResearchConceptsTumor plasma cellsMultiple myelomaPlasma cellsResidual diseasePlasma samplesPilot studySecond-line therapyCell-free tumor DNA analysisMultiple myeloma patientsConventional laboratory parametersSerial plasma samplesMinimal residual diseaseBone marrow aspirateNumber of PCsTumor DNA analysisA Pilot StudyClonal IgH rearrangementsClonal IgH gene rearrangementsIgH gene rearrangementTumor clonotypesComplete responseLaboratory parametersMyeloma patientsCfDNA levelsTumor levels